Filing Summary
Company and period: The source filing identifies the registrant as Adtalem Global Education Inc. (NYSE: ATGE), not Covista Inc. It is a Form 10-Q for the quarter ended December 31, 2022, covering the second quarter and first six months of fiscal 2023. Financial amounts below are in U.S. dollars.
Business Context
Adtalem provides post-secondary education through Chamberlain University, Walden University, and its medical and veterinary schools. Results are presented for continuing operations; the former Financial Services businesses were sold in 2022 and classified as discontinued operations.
Key Financial Metrics
| Metric | Quarter ended Dec. 31, 2022 | Six months ended Dec. 31, 2022 |
|---|---|---|
| Revenue | $363.3 million | $717.9 million |
| Operating income | $46.0 million | $69.1 million |
| Operating margin | 12.7% | 9.6% |
| Income from continuing operations | $23.6 million | $29.5 million |
| Net income (including discontinued operations) | $24.1 million | $26.3 million |
| Diluted EPS | $0.52 | $0.57 |
| Operating cash flow | Not stated separately for the quarter | $42.3 million from continuing operations; $41.4 million including discontinued operations |
- Quarterly revenue declined 2.1% year over year. Six-month revenue rose 8.7% as reported, including $64.2 million attributable to the prior-year timing of the Walden acquisition; organic revenue declined 1.0%.
- Quarterly adjusted operating income, a non-GAAP measure, increased 13.2% to $79.5 million; adjusted net income rose 43.4% to $54.2 million, or $1.17 diluted adjusted EPS.
- Cash and cash equivalents were $207.8 million at December 31, 2022, down from $347.0 million at June 30, 2022. Total assets were $2.84 billion and shareholders’ equity was $1.52 billion.
- Debt principal outstanding was $708.3 million: $405.0 million of 5.50% secured notes due 2028 and $303.3 million under Term Loan B. The $400 million revolver was undrawn and fully available. The Term Loan B rate was 8.39% at quarter-end.
- Quarterly interest expense fell to $15.6 million from $25.9 million; six-month expense fell to $33.3 million from $73.3 million. Debt repayment drove the decline, partly offset by higher rates.
Material Changes and Segment Trends
- Chamberlain: Quarterly revenue increased 1.6% to $141.4 million; November enrollment was down 0.8% year over year. Adjusted operating income increased to $33.2 million.
- Walden: Quarterly revenue decreased 6.2% to $131.9 million; enrollment at December 31 was down 7.8%. Adjusted operating income declined 10.5% to $29.0 million, with lower revenue cited as the main driver.
- Medical and Veterinary: Quarterly revenue decreased 1.6% to $90.0 million, principally due to increased scholarships; adjusted operating income increased 16.8% to $23.0 million.
- Consolidated quarterly operating income improved substantially year over year, helped by lower education-service costs and lower intangible amortization. Reported results also include acquisition/integration and restructuring expenses.
- During the six months, Adtalem prepaid $150 million of Term Loan B debt and repurchased a small amount of notes. It completed a $150 million accelerated share repurchase, settling a final $13.2 million obligation in cash.
Outlook, Risks, and Unusual Items
- No full-year revenue or earnings guidance is stated in the provided filing text. Management estimated fiscal 2023 capital spending of $35 million to $45 million; $9.7 million had been spent in the first six months.
- Management expects additional Walden integration and transformation costs through the remainder of fiscal 2023 and fiscal 2024. It says healthcare-worker stress and lingering COVID-19 effects may continue to weigh on enrollment and results.
- Adtalem reported an $84.0 million surety-backed letter of credit for Walden’s Title IV participation. In January 2023, the Department of Education requested an additional $76.1 million letter of credit related to review of the acquisition-date consolidated balance sheet, due within 45 days of the request. Management anticipated the Department may also impose added oversight or collateral requirements following Walden’s acquisition.
- Education operations depend materially on federal student-aid programs and regulatory approvals. Walden was operating under a temporary provisional PPA, and several medical/veterinary schools had provisional certification histories; failure to meet requirements could affect Title IV eligibility.
- Interest-rate exposure remains: management estimated a 100-basis-point increase would add about $3.0 million to annual interest expense on Term Loan B borrowings. The company expected to transition its credit agreement from LIBOR to SOFR during fiscal 2023.
- Other notable items include a $5.0 million impairment of an equity investment, $16.4 million of six-month restructuring charges, and continuing DeVry-related litigation and settlement activity. The filing describes several pending matters, including a Walden student class action; possible outcomes for certain matters are not quantified.
Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is for Adtalem Global Education Inc., despite the request metadata naming Covista Inc.
- Review enrollment trends, particularly the continuing declines at Walden and the effects of healthcare-worker stress on demand.
- Track the Department of Education’s requested $76.1 million letter of credit, Walden’s provisional certification, and any additional Title IV conditions.
- Assess whether operating cash generation can support capital spending, interest costs, and planned operations as cash balances decline and floating-rate debt remains outstanding.
- Separate GAAP performance from management’s non-GAAP adjusted results, and monitor integration, restructuring, litigation, and other excluded costs.